On the Radar: November's biotech stocks to watch

[SOURCE: Fierce Biotech] This month three Canaccord Adams analysts--Adam Cutler, George Farmer and Ritu Baral (bios and photos)--weigh in on five developers that are facing pivotal events. A timely regulatory approval would mean a lot for one of these companies, another is pushing a new cancer therapy into crucial late-stage trials and a third is fishing for a potential partnership that could make a big difference as it advances three programs in the clinic. A well-timed NDA filing could set the stage for another pact while our fifth company faces a near-term decision from the FDA and some big decisions on a possible partner. Featured in this issue of On the Radar are Cadence Pharmaceuticals, Micromet, Momenta Pharmaceuticals, Pharmasset, and Protalix BioTherapeutics.


Post a Comment